These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29189588)

  • 1. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
    Kim MJ; Kong SY; Nam BH; Kim S; Park YI; Park SR
    Pharmacogenet Genomics; 2018 Jan; 28(1):23-30. PubMed ID: 29189588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
    Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
    Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.
    Kim YW; Kim MJ; Ryu KW; Lim HS; Lee JH; Kong SY; Lee JS; Choi IJ; Kim CG; Lee JY; Cho SJ; Kook MC; Park YI; Kim SK; Park SR
    Gastric Cancer; 2016 Apr; 19(2):586-596. PubMed ID: 25851942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
    Wan Y; Hui H; Wang X; Wu J; Sun S
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
    Park SR; Kong SY; Nam BH; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim YW; Ryu KW; Lee JH; Rhee J; Park YI; Kim NK
    Br J Cancer; 2011 Mar; 104(7):1126-34. PubMed ID: 21364592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
    He MM; Zhang DS; Wang F; Wang ZX; Yuan SQ; Wang ZQ; Luo HY; Ren C; Qiu MZ; Jin Y; Wang DS; Chen DL; Zeng ZL; Li YH; He YY; Hao YT; Guo P; Wang FH; Zeng YX; Xu RH
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):69-79. PubMed ID: 27913881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
    Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
    Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status.
    Jeung HC; Rha SY; Shin SJ; Ahn JB; Noh SH; Roh JK; Chung HC
    Br J Cancer; 2007 Aug; 97(4):458-63. PubMed ID: 17653073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
    Kim KP; Jang G; Hong YS; Lim HS; Bae KS; Kim HS; Lee SS; Shin JG; Lee JL; Ryu MH; Chang HM; Kang YK; Kim TW
    Br J Cancer; 2011 Feb; 104(4):605-12. PubMed ID: 21326246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.
    Kong SY; Lim HS; Nam BH; Kook MC; Kim YW; Ryu KW; Lee JH; Choi IJ; Lee JS; Park YI; Kim NK; Park SR
    Pharmacogenomics; 2009 Jul; 10(7):1147-55. PubMed ID: 19604090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
    Tanaka H; Kanda M; Morita S; Taguri M; Nishikawa K; Shimada M; Muguruma K; Koeda K; Takahashi M; Nakamori M; Konno H; Tsuji A; Hosoya Y; Shirasaka T; Yamamitsu S; Sowa M; Kitajima M; Okajima M; Kobayashi M; Sakamoto J; Saji S; Hirakawa K
    Int J Clin Oncol; 2017 Dec; 22(6):1052-1059. PubMed ID: 28667408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
    Hwang IG; Ji JH; Kang JH; Lee HR; Lee HY; Chi KC; Park SW; Lee SJ; Kim ST; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
    J Geriatr Oncol; 2017 May; 8(3):170-175. PubMed ID: 28119041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis.
    He AB; Peng XL; Song J; Zhang JX; Dong WG; Luo RF; Tang Y
    World J Gastroenterol; 2015 Apr; 21(14):4358-64. PubMed ID: 25892887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
    He MM; Wu WJ; Wang F; Wang ZQ; Zhang DS; Luo HY; Qiu MZ; Wang FH; Ren C; Zeng ZL; Xu RH
    PLoS One; 2013; 8(12):e82798. PubMed ID: 24349363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    Lee JL; Kang YK; Kang HJ; Lee KH; Zang DY; Ryoo BY; Kim JG; Park SR; Kang WK; Shin DB; Ryu MH; Chang HM; Kim TW; Baek JH; Min YJ
    Br J Cancer; 2008 Aug; 99(4):584-90. PubMed ID: 18665164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
    Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
    Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
    Kim ST; Hong YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Lee JW; Jo SJ; Park YS
    BMC Cancer; 2014 Nov; 14():883. PubMed ID: 25424120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
    Lee KW; Kim BJ; Kim MJ; Han HS; Kim JW; Park YI; Park SR
    Cancer Res Treat; 2017 Jul; 49(3):706-716. PubMed ID: 27764906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.